Noxopharm (NOX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Noxopharm’s Lupus Drug Clears Final Preclinical HurdleApril 14, 2025 | tipranks.comNoxopharm Reports Half-Year Financial Results and Strategic FocusFebruary 24, 2025 | tipranks.comBargain Barrel: Four ASX cancer-fighting stocks with market caps under $35 millionFebruary 24, 2025 | msn.comNoxopharm jumps as flagship lupus drug clears first-pass in vitro safety testsFebruary 4, 2025 | msn.comNoxopharm Issues New Unquoted Equity SecuritiesJanuary 10, 2025 | tipranks.comNoxopharm Achieves Key Approvals at Annual MeetingNovember 19, 2024 | markets.businessinsider.comNoxopharm Gains Investor Interest and Expands Drug TrialsOctober 28, 2024 | markets.businessinsider.comDiscovering Noxopharm And 2 Other ASX Penny Stocks To WatchOctober 22, 2024 | finance.yahoo.comThe morning catch up: Tech leads US markets to new records as oil pressures easeOctober 11, 2024 | au.investing.comNoxopharm ‘a step closer to the clinic’ upon signing manufacturer for SOF-SKN productionOctober 10, 2024 | au.investing.comHere's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn SituationAugust 23, 2024 | sg.finance.yahoo.comLiveHire claims gold after stellar all-cash takeover bidAugust 16, 2024 | msn.comBig Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic CancerAugust 7, 2024 | msn.comCheck Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winnersJuly 31, 2024 | msn.comNoxopharm Ltd NOXJuly 31, 2024 | morningstar.comNoxopharm Limited (NOX.XA)May 29, 2024 | finance.yahoo.comThe morning catch up: US and UK markets on a break as ASX looks set to move higher todayMay 27, 2024 | au.investing.comASX Small Caps Lunch Wrap: Whose flashed boobies have ruined the fun for everyone this week?May 15, 2024 | msn.comNoxopharm Limited (NOX.AX)April 20, 2024 | nz.finance.yahoo.comFIVE at FIVE AU: ASX up as gold ralliesApril 4, 2024 | au.investing.comASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?February 28, 2024 | msn.comGenetic Technologies Ltd. ADRFebruary 17, 2024 | wsj.comThe morning catch up: ASX set to rise; Wall Street mixed as investors await inflation dataFebruary 12, 2024 | au.investing.comNoxopharm extends strategic partnership with Hudson Institute of Medical ResearchFebruary 12, 2024 | au.investing.comNoxopharm LimitedFebruary 6, 2024 | afr.comFIVE at FIVE AU: ASX logs strong day; retail figures better than expectedJanuary 10, 2024 | proactiveinvestors.comASX December Winners: The best 50 stocks as optimism pushes markets near record highJanuary 1, 2024 | msn.comNoxopharm boosts cash position with A$6 million R&D rebateNovember 15, 2023 | proactiveinvestors.comNoxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study showsOctober 17, 2023 | proactiveinvestors.comASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 studyOctober 17, 2023 | msn.comNoxopharm soars as study shows SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammationOctober 17, 2023 | proactiveinvestors.comNoxopharm and Hudson Institute collaborate on pioneering mRNA researchOctober 12, 2023 | au.investing.comNoxopharm talks partnership with Hudson Institute of Medical ResearchOctober 11, 2023 | proactiveinvestors.comClosing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastieOctober 4, 2023 | msn.comMarket Highlights: Wall Street cops it on strong jobs but who cares when we’ve got all these lovely ASX lithium leadsOctober 4, 2023 | msn.comASX healthcare stock Noxopharm explodes 165% on FDA newsOctober 4, 2023 | fool.com.auNoxopharm granted US orphan drug status for CRO-67 pancreatic cancer therapyOctober 3, 2023 | proactiveinvestors.com.auASX Health Stocks: Anatara moves rapidly to Stage 2 in Phase 1/2 bowel syndrome trialSeptember 28, 2023 | msn.comNoxopharm presents encouraging data on CRO-67 at AACR Pancreatic Cancer conferenceSeptember 28, 2023 | au.investing.comNoxopharm welcomes preliminary data on Veyonda drug trialMay 25, 2023 | proactiveinvestors.com.auNoxopharm welcomes presentation of Sofra™ inflammation technologyMay 22, 2023 | proactiveinvestors.com.auNoxopharm hails new Sofra™ drug inflammation resultsMay 22, 2023 | proactiveinvestors.comMarket Highlights: FAANG stocks at one-year high, and will US Fed skip a meeting in June?May 18, 2023 | msn.comNoxopharm reveals new Sofra™ drug reduces inflammationMay 18, 2023 | proactiveinvestors.com.auNoxopharm has Sofra™ inflammation research presented at European Molecular Biology Organisation event; commercial opportunities awaitMay 17, 2023 | proactiveinvestors.comSoft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsightMay 10, 2023 | finance.yahoo.comNoxopharm to prioritise Chroma™ and Sofra™ programs; Veyonda trials to disbandApril 5, 2023 | proactiveinvestors.com.auASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030March 28, 2023 | msn.comNoxopharm reveals proprietary mRNA vaccine enhancer technologyMarch 27, 2023 | proactiveinvestors.comNoxopharm tapped to deliver oral presentation on lupus research at International LUPUS 2023 ConferenceFebruary 21, 2023 | proactiveinvestors.com.au Get Noxopharm News Delivered to You Automatically Sign up to receive the latest news and ratings for NOX and its competitors with MarketBeat's FREE daily newsletter. Email Address NOX Media Mentions By Week NOX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NOX News Sentiment▼0.000.85▲Average Medical News Sentiment NOX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NOX Articles This Week▼00▲NOX Articles Average Week Get Noxopharm News Delivered to You Automatically Sign up to receive the latest news and ratings for NOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MDNA News Today SVA News Today OBI News Today COV News Today ONC News Today ETX News Today SBTX News Today MBX News Today FUM News Today GSD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:NOX) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Noxopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Noxopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NOX Stock Free NOX Stock Alerts